Do analysts rate GMAB or TAK?

Genmab A/S presently has a consensus price target of $39.28, indicating a potential upside of 36.05%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor GMAB or TAK?

In the previous week, Genmab A/S had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Genmab A/S and 4 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 1.03 beat Takeda Pharmaceutical's score of 0.42 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ARGX or GMAB?

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.52 $1.29B $26.04 35.26 Genmab A/S $3.90B 4.61 $963M $1.32 21.87

Is ARGX or GMAB more profitable?

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 70.27% beat Genmab A/S's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 70.27% 59.26% Genmab A/S 21.05% 15.34% 8.94%

Does the media prefer ARGX or GMAB?

In the previous week, argenex had 36 more articles in the media than Genmab A/S. MarketBeat recorded 42 mentions for argenex and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.03 beat argenex's score of 1.00 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 16 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMAB or RVMD?

In the previous week, Revolution Medicines had 17 more articles in the media than Genmab A/S. MarketBeat recorded 23 mentions for Revolution Medicines and 6 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 1.35 beat Genmab A/S's score of 1.03 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 17 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TEVA or GMAB?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 6 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat Genmab A/S's score of 1.03 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONC or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Genmab A/S 21.05% 15.34% 8.94%

Does the media prefer ONC or GMAB?

In the previous week, BeOne Medicines had 11 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for BeOne Medicines and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.03 beat BeOne Medicines' score of 0.79 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 8 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genmab A/S (GMAB) Competitors

$28.87 -0.30 (-1.03%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$28.88 +0.01 (+0.03%)

As of 07/24/2026 07:34 PM Eastern

Compare

GMAB vs. TAK, ARGX, RVMD, TEVA, and ONC

Should you buy Genmab A/S stock or one of its competitors? MarketBeat compares Genmab A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genmab A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Genmab A/S compare to Takeda Pharmaceutical?

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Takeda Pharmaceutical's net margin of 4.31%. Genmab A/S's return on equity of 15.34% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Genmab A/S presently has a consensus price target of $39.28, indicating a potential upside of 36.05%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	44.19

In the previous week, Genmab A/S had 2 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Genmab A/S and 4 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 1.03 beat Takeda Pharmaceutical's score of 0.42 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to argenex?

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

60.3% of argenex shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

argenex presently has a consensus target price of $1,050.50, indicating a potential upside of 14.41%. Genmab A/S has a consensus target price of $39.28, indicating a potential upside of 36.05%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, argenex had 36 more articles in the media than Genmab A/S. MarketBeat recorded 42 mentions for argenex and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.03 beat argenex's score of 1.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	16 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 70.27% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	70.27%	59.26%
Genmab A/S	21.05%	15.34%	8.94%

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.52	$1.29B	$26.04	35.26
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87

Summary

argenex beats Genmab A/S on 14 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Genmab A/S (NASDAQ:GMAB) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Genmab A/S has a net margin of 21.05% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Revolution Medicines	N/A	-83.22%	-59.06%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

In the previous week, Revolution Medicines had 17 more articles in the media than Genmab A/S. MarketBeat recorded 23 mentions for Revolution Medicines and 6 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 1.35 beat Genmab A/S's score of 1.03 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	17 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S currently has a consensus price target of $39.28, suggesting a potential upside of 36.05%. Revolution Medicines has a consensus price target of $144.67, suggesting a potential downside of 23.55%. Given Genmab A/S's higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

Genmab A/S and Revolution Medicines tied by winning 8 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 6 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat Genmab A/S's score of 1.03 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.05	$1.41B	$1.33	23.15
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87

Genmab A/S has a net margin of 21.05% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Genmab A/S	21.05%	15.34%	8.94%

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, suggesting a potential upside of 35.71%. Genmab A/S has a consensus price target of $39.28, suggesting a potential upside of 36.05%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Genmab A/S on 10 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S has lower revenue, but higher earnings than BeOne Medicines. Genmab A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74B	6.23	$286.93M	$4.47	72.91
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87

In the previous week, BeOne Medicines had 11 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for BeOne Medicines and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.03 beat BeOne Medicines' score of 0.79 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	8 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

BeOne Medicines currently has a consensus price target of $394.00, indicating a potential upside of 20.90%. Genmab A/S has a consensus price target of $39.28, indicating a potential upside of 36.05%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Genmab A/S	21.05%	15.34%	8.94%

Summary

BeOne Medicines beats Genmab A/S on 9 of the 16 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.19B	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	21.87	21.48	27.14	23.64
Price / Sales	4.61	169.92	517.01	89.03
Price / Cash	18.12	157.90	50.54	59.64
Price / Book	3.17	7.88	10.28	6.07
Net Income	$963M	$23.86M	$3.60B	$331.99M
7 Day Performance	0.52%	-3.82%	-1.27%	-0.63%
1 Month Performance	10.44%	-2.61%	-0.37%	-2.00%
1 Year Performance	23.38%	32.79%	18.30%	13.62%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	4.7872 of 5 stars	$28.87 -1.0%	$39.28 +36.1%	+22.2%	$18.19B	$3.90B	21.87	3,029	Positive News Analyst Upgrade
TAK Takeda Pharmaceutical	1.8229 of 5 stars	$17.05 -0.6%	N/A	+17.6%	$54.95B	$28.32B	43.71	47,000	News Coverage Upcoming Earnings Gap Up
ARGX argenex	4.0674 of 5 stars	$846.19 -1.7%	$1,037.61 +22.6%	+55.2%	$53.84B	$4.25B	37.68	1,863	Trending News Earnings Report Analyst Forecast Analyst Revision
RVMD Revolution Medicines	1.8244 of 5 stars	$180.39 -3.1%	$144.06 -20.1%	+408.4%	$39.58B	$11.58M	N/A	250	News Coverage Positive News Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.7187 of 5 stars	$30.97 -3.3%	$41.78 +34.9%	+88.2%	$36.83B	$17.26B	23.28	33,950	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, RVMD, TEVA, and ONC

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Revolution Medicines?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, RVMD, TEVA, and ONC

How does Genmab A/S compare to Takeda Pharmaceutical?

Which has more risk & volatility, GMAB or TAK?

Do insiders and institutionals believe in GMAB or TAK?

Is GMAB or TAK more profitable?

Do analysts rate GMAB or TAK?

Which has preferable valuation and earnings, GMAB or TAK?

Does the media favor GMAB or TAK?

Summary

How does Genmab A/S compare to argenex?

Do insiders & institutionals hold more shares of ARGX or GMAB?

Do analysts rate ARGX or GMAB?

Does the media prefer ARGX or GMAB?

Which has more risk and volatility, ARGX or GMAB?

Is ARGX or GMAB more profitable?

Which has higher valuation and earnings, ARGX or GMAB?

Summary

How does Genmab A/S compare to Revolution Medicines?

Is GMAB or RVMD more profitable?

Do insiders & institutionals have more ownership in GMAB or RVMD?

Which has more volatility & risk, GMAB or RVMD?

Which has better earnings & valuation, GMAB or RVMD?

Does the media prefer GMAB or RVMD?

Do analysts rate GMAB or RVMD?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Does the media prefer TEVA or GMAB?

Which has more risk and volatility, TEVA or GMAB?

Which has higher earnings & valuation, TEVA or GMAB?

Is TEVA or GMAB more profitable?

Do analysts prefer TEVA or GMAB?

Do institutionals & insiders have more ownership in TEVA or GMAB?

Summary

How does Genmab A/S compare to BeOne Medicines?

Do insiders and institutionals hold more shares of ONC or GMAB?

Which has preferable valuation & earnings, ONC or GMAB?

Does the media prefer ONC or GMAB?

Which has more risk and volatility, ONC or GMAB?

Do analysts recommend ONC or GMAB?

Is ONC or GMAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools